Skip to main content

Table 1 Univariate analysis of the risk factors for acute pancreatitis after PTBS

From: Prognostic nomogram for acute pancreatitis after percutaneous biliary stent insertion in patients with malignant obstruction

 

All patients

Groups

 

Variables

(n = 314)

Non-AP (n = 273)

AP (n = 41)

Z / χ2

p-value

Patient characteristics, frequency (%)

Gender

   

0.856

0.355

 Male

159 (50.6)

141 (51.6)

18 (43.9)

  

 Female

155 (49.4)

132 (48.4)

23 (56.1)

  

Age

   

8.829

0.003

  ≥ 60 years

196 (62.4)

179 (65.6)

17 (41.5)

  

  < 60 years

118 (37.6)

94 (34.4)

24 (58.5)

  

Primary tumor

   

0.509

0.476

 Pancreatic cancer

46 (14.6)

42 (15.4)

4 (15.0)

  

 Non-Pancreatic cancer

268 (85.4)

231 (84.6)

37 (85.0)

  

Hypertension

   

0.231

0.630

 Yes

112 (35.7)

96 (35.2)

16 (39.0)

  

 No

202 (64.3)

177 (64.8)

25 (61.0)

  

Diabetes mellitus

   

2.764

0.096

 Yes

49 (15.6)

39 (14.3)

10 (24.4)

  

 No

265 (84.4)

234 (85.7)

31 (75.6)

  

Cardiovascular disease

   

0.652

0.419

 Yes

30 (9.6)

28 (10.3)

2 (4.9)

  

 No

284 (90.4)

245 (89.7)

39 (85.1)

  

Previous biliary drainage

   

0.067

0.795

 Yes

132 (42.0)

114 (41.8)

18 (43.9)

  

 No

182 (58.0)

159 (58.2)

23 (56.1)

  

Preoperative infection

   

0.994

0.319

 Yes

94 (29.9)

79 (28.9)

15 (36.6)

  

 No

220 (70.1)

194 (71.1)

26 (63.4)

  

Location of stricture

   

3.542

0.170

 Upper bile duct

92 (29.3)

85 (31.1)

7 (17.1)

  

 Lower bile duct

151 (48.1)

127 (46.5)

24 (58.5)

  

 Whole bile duct

71 (22.6)

61 (22.4)

10 (24.4)

  

Laboratory indices, median (IQR)

 ALT (U/L)

73.3 (42.4–124.5)

72.9 (42.5–127.0)

77.3 (42.7–121.8)

-0.183

0.855

 AST (U/L)

89.6 (56.4–145.9)

87.8 (56.1–147.0)

98.8 (63.9–159.2)

-0.602

0.547

 ALP (U/L)

420.3 (255.0–701.4)

414.6 (270.3–684.3)

491.0 (208.9–808.9)

-0.123

0.902

 TBIL (μmol/L)

197.5 (111.8–318.9)

192.5 (115.6–320.9)

203.2 (94.6–291.4)

-0.306

0.759

 DBIL (μmol/L)

152.2 (94.0–240.8)

156.0 (94.3–245.7)

145.5 (80.6–232.1)

-0.468

0.639

hs-CRP, mg/L

   

2.092

0.148

  ≥ 8

108

98 (35.9)

10 (24.4)

  

  < 8

206

175 (64.1)

31 (75.6)

  

Procedure characteristics, frequency (%)

Operation time

   

0.128

0.721

  ≥ 60 min

68 (21.7)

60 (22.0)

8 (19.5)

  

  < 60 min

246 (78.3)

213 (78.0)

33 (80.5)

  

External drainage tube

   

0.011

0.918

 Yes

67 (21.3)

58 (21.2)

9 (22.0)

  

 No

247 (78.7)

215 (78.8)

32 (78.0)

  

Iodine-125 seed strand

   

1.208

0.272

 Yes

64 (20.4)

53 (19.4)

11 (26.8)

  

 No

250 (79.6)

220 (80.6)

30 (73.2)

  

Stent length

   

2.890

0.236

 6 cm

119 (37.9)

106 (38.8)

13 (31.7)

  

 8 cm

158 (50.3)

136 (50.6)

20 (48.8)

  

 10 cm

37 (11.8)

31 (10.6)

8 (19.5)

  

Number of stents

   

1.044

0.307

 One

196 (62.4)

182 (66.7)

24 (58.5)

  

 Multiple

118 (37.6)

91 (33.3)

17 (41.5)

  

Stent placement across the papilla

29.150

 < 0.001

 Yes

131 (41.7)

98 (35.9)

33 (80.5)

  

 No

183 (58.3)

175 (64.1)

8 (19.5)

  

Visualization of the pancreatic duct

64.377

 < 0.001

 Yes

33 (10.5)

14 (5.1)

19 (46.3)

  

 No

281 (89.5)

259 (94.9)

22 (53.7)

  
  1. * Operation time was defined as the time from successful puncture to repeat cholangiography confirmed with stent patency
  2. * Stent length was evaluated as the maximum length while multiple-stent insertion
  3. * IQR Inter-quartile range, ALT Alanine aminotransferase, AST Aspartate aminotransferase, ALP Alkaline phosphatase, TBIL Total bilirubin, DBIL Direct bilirubin, hs-CRP Hypersensitive C-reactive protein